New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|April 6, 2017
Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma
Author(s)Yousef Zakharia, MD
Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma.
Advertisement
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
Denosumab Biosimilar Approved For Existing Oncology Indications
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
Tile-Based Radiation Improves Local Control in Resected Brain Metastases
5